Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV

Résumé fourni par la source

Dolutegravir resistance is predominantly reported in antiretroviral therapy-experienced individuals. We describe an infant who developed high-level resistance to abacavir, lamivudine, and dolutegravir within 97 days of initiation, despite initial wild-type infection. Causative factors likely include probable sub-therapeutic antiretroviral drug levels, poor tolerance, severe immunocompromise, and a high pre-treatment viral load. What this study adds: The evolution of DTG resistance from a confirmed transmitted wild-type virus in this infant is more rapid than previously described. Identification of risk factors for developing DTG resistance in infants requires further investigation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.